Henry Schein, Inc. (NASDAQ:HSIC) Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC boosted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 80.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,940 shares of the company’s stock after purchasing an additional 3,096 shares during the period. Merit Financial Group LLC’s holdings in Henry Schein were worth $525,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HSIC. Lazard Asset Management LLC raised its holdings in shares of Henry Schein by 1,303.3% in the third quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after buying an additional 1,158,451 shares during the last quarter. Boston Partners raised its holdings in shares of Henry Schein by 4,975.9% in the third quarter. Boston Partners now owns 1,080,598 shares of the company’s stock worth $80,229,000 after buying an additional 1,059,309 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Henry Schein by 7.3% in the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock worth $350,392,000 after buying an additional 322,649 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of Henry Schein in the third quarter worth $19,864,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Henry Schein in the third quarter worth $16,650,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Up 3.9 %

Shares of NASDAQ HSIC opened at $71.20 on Wednesday. The company’s 50-day simple moving average is $73.08 and its 200-day simple moving average is $72.34. Henry Schein, Inc. has a 52-week low of $60.01 and a 52-week high of $82.63. The firm has a market cap of $9.15 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.68 and a beta of 0.87. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. During the same quarter last year, the business earned $1.21 earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. Equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Insider Activity

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Barrington Research increased their price objective on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a research note on Monday, February 26th. Piper Sandler increased their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. JPMorgan Chase & Co. increased their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, Evercore ISI raised their price target on shares of Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.